[go: up one dir, main page]

RU2006111491A - Новые противоопухолевые соединения - Google Patents

Новые противоопухолевые соединения Download PDF

Info

Publication number
RU2006111491A
RU2006111491A RU2006111491/04A RU2006111491A RU2006111491A RU 2006111491 A RU2006111491 A RU 2006111491A RU 2006111491/04 A RU2006111491/04 A RU 2006111491/04A RU 2006111491 A RU2006111491 A RU 2006111491A RU 2006111491 A RU2006111491 A RU 2006111491A
Authority
RU
Russia
Prior art keywords
mehex
val
phe
orn
amino acid
Prior art date
Application number
RU2006111491/04A
Other languages
English (en)
Other versions
RU2395520C2 (ru
Inventor
ПАЛОМЕРА Фернандо АЛЬБЕРИСИО (ES)
ПАЛОМЕРА Фернандо АЛЬБЕРИСИО
ДОНИС Ариадна ФЕРНАНДЕС (ES)
ДОНИС Ариадна ФЕРНАНДЕС
ЛЬЕДО Эрнест ХИРАЛЬД (ES)
ЛЬЕДО Эрнест ХИРАЛЬД
КАНТАДОР Каролина ГРАСИЯ (ES)
КАНТАДОР Каролина ГРАСИЯ
РОДРИГЕС Пилар ЛОПЕС (ES)
РОДРИГЕС Пилар ЛОПЕС
КОЛОМЕР Сон ВАРОН (ES)
КОЛОМЕР Соня ВАРОН
МАРЧАНТЕ Кармен КУЭВАС (ES)
МАРЧАНТЕ Кармен КУЭВАС
МАСИЯ Анхель ЛОПЕС (ES)
МАСИЯ Анхель ЛОПЕС
СОЛЬОСО Андрес ФРАНСЕСЧ (ES)
Сольосо Андрес Франсесч
ГАРСИЯ Хосе-Карлос ХИМЕНЕС (ES)
ГАРСИЯ Хосе-Карлос ХИМЕНЕС
ЭКСПОЗИТО Мириам РОЙО (ES)
ЭКСПОЗИТО Мириам РОЙО
Original Assignee
Фарма Мар С.А.У. (Es)
Фарма Мар С.А.У.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Фарма Мар С.А.У. (Es), Фарма Мар С.А.У. filed Critical Фарма Мар С.А.У. (Es)
Publication of RU2006111491A publication Critical patent/RU2006111491A/ru
Application granted granted Critical
Publication of RU2395520C2 publication Critical patent/RU2395520C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K11/00—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K11/02—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof cyclic, e.g. valinomycins ; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Claims (14)

1. Соединение на основе структуры кахалалида F и которое отличается, по меньшей мере, в одном отношении.
2. Соединение по п.1 формулы (1)
Figure 00000001
где одна или более аминокислот замещены другими природными или неприродными аминокислотами, защищенными органическими группами или удалены.
3. Соединение по п.1 или 2, где метилгексаноильная группа замещена другой карбоксильной группой или удалена.
4. Соединение по п.1, где аминокислота в циклической части отличается от таковой в кахалалиде F.
5. Соединение по п.4, где L-Phe изменена в позиции 3.
6. Соединение по п.5, где аминокислота в позиции 3 представляет собой защищенную L-Phe.
7. Соединение по п.5, где аминокислота в позиции 3 представляет собой другую природную аминокислоту или является неприродной аминокислотой.
8. Соединение по п.1 или 2, где L-Orn изменена в позиции 8.
9. Соединение по п.8, где аминокислота в позиции 8 представляет собой защищенную L-Orn.
10. Соединение по п.5, где аминокислота в позиции 8 представляет собой другую природную аминокислоту или является неприродной аминокислотой.
11. Соединение п.1 или 2, где боковая цепь изменена.
12. Соединение по п.11, где концевая ацильная группа изменена.
13. Соединение по п.12, где концевой ацильной группой является 4(S)-метилгексил.
14. Соединение на основе структуры кахалалида F формулы (1), обозначаемого KF, и выбираемое из группы, состоящей из
[D-Thr6]-KF, [D-Ser6]-KF, [Glu8]-KF, [Lys8]-KF, [Val12]-KF, [D-Thr12]-KF, [D-Cha13]-KF, [hCh11]-KF, [hCh11, D-Cha13]-KF, [D-Cha4, D-Cha5, D-Cha7]-KF, [D-Val5, D-Val7]-KF, [Icos14]-KF, [(c/t)-4-Me-cHexa14]-KF, [Und14]-KF, [(4R)-MeHex14]-KF, [(4RS)-MeHex14]-KF, [Oct14]-KF, [p-MeBza14]-KF, [Bza14]-KF, [p-CF3Bza14]-KF, [3,5-dFPhAc14]-KF, [Pipe14]-KF, [p-CF3Cinn14]-KF, [p-CF3PhAc14]-KF, [PFh14]-KF, [6-OHep14]-KF, [6,6-dFHep14]-KF, [4-GuBut14]-KF, [Lys8, (4S)-MeHex14]-KF, [noVal11, noThr12, noD-Val13]-KF, [noVal11, noThr12, noD-Val13, Mst14]-KF, [Gly13]-KF, [D-Ala13]-KF, [D-Leu13]-KF, [D-Phe13]-KF, [D-Pro13]-KF, [Val13]-KF, [D-Glu13]-KF, [D-Gln13]-KF, [D-Thr13]-KF, [Gly11]-KF, [Phe11]-KF, [Ala11]-KF, [Leu11]-KF, [D-Val11]-KF, [Pro11]-KF, [Gln11]-KF, [Orn11]-KF, [Thr11]-KF, [Gly11]-KF, [Ala12, noD-Val13]-KF, [Gly12, noD-Val13]-KF, [Leu12, noD-Val13]-KF, [Pro12, noD-Val13]-KF, [Glu12, noD-Val13]-KF, [Orn12, noD-Val13]KF, [Gln12, noD-Val13]-KF, [Pro9, (4S)-MeHex14]-KF, [D-Pip9, (4S) MeHex14]-KF, [D-Tic9, (4S) MeHex14]-KF, [(5R)-Ph-Pro9, (4S)-MeHex14]-KF, [hCh3]-KF, [D,L-Ser2]-KF, [Gly2]-KF, [Aib2]-KF, [Dha2]-KF, [Trp3]-KF, [D-Val1, D-Phe3, Val4, allo-Ile5, allo-Thr6, allo-Ile7, D-Orn8, Pro9, Val10, D-Val11, D-Thr12, Val13]KF, [Phe(3,4-Cl2)3, (4S)-MeHex14]-KF, [Phe(F5)3, (4S)-MeHex14]-KF, [Phe(4-I)3, (4S)-MeHex14]-KF, [Phe(4-NO2)3, (4S)-MeHex14]-KF, [Phe(4-F)3, (4S)-MeHex14]-KF, [Tyr(Me)3, (4S)-MeHex14]-KF, [Thi3, (4S)-MeHex14]-KF, [Tic3, (4S)-MeHex14]-KF, [Tyr3, (4S)-MeHex14]-KF, [Oic3, (4S)-MeHex14]-KF, [NMePhe3, (4S)-MeHex14]-KF, [Phe(2-Cl)3-KF, [Phe(3-Cl)3]-KF, [Phe(4-Cl)3]-KF, [Phe(3,4-F2)3]-KF, [NaI3]-KF, [Bip3]-KF, [Phg3]-KF, [Phe(3,4-Cl2)3 p-CF3Cinn14]-KF, [N(Me)2, N′(Me)2-Arg8]-KF, [N(Me, Ph), N′(Me)2-Arg8]-KF, [N(CH2)4, N′(Me)2-Arg8]-KF, [N(CH2)4, N'(CH2)4-Arg8]-KF, [Nδ(CHN)(CH2)4-N'(CH2)4)-Orn8]-KF, [Nε(Me)3-Lys8, (4S)-MeHex14]-KF, [Thr(OTFA)12, (4S)-MeHex14]-KF, [Orn(NδTFA)8, Thr(OTFA)12, (4S)-MeHex14]-KF, [Orn(NδTFA)8, (4S)-MeHex14]-KF, [Thr(OTFA)12, Lit(OTFA)14]-KF, [no 5-MeHex14, N(Hep)2-Val13]-KF, [Orn(Biot)8]-KF, [L-Val-d8 11]-KF, [AM14]-KF, [AO14]-KF, [C(=N(CH3)2)14]-KF, [D-Ile7]-KF, [D-Val7]-KF, [D-Orn8, L-Pro9]-KF, [D-Cys7, L-Cys11]-KF, [D-Cys7, D-Cys10]-KF, [D-homoCys7, D-homoCys10]-KF, [Gly12]-KF, [Ala12]-KF, [Leu12]-KF, [Phe12]-KF, [Glu12]-KF, [Orn12]-KF, [Pro12]-KF, [D-Orn13]-KF, [Gln12]-KF и [D-Val1]-KF,
где аминокислота или группа, указанная в квадратных скобках, является модификацией, введенной в структуру кахалалида F.
RU2006111491/04A 2003-09-09 2004-09-09 Производные кахалалида f RU2395520C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0321066.3A GB0321066D0 (en) 2003-09-09 2003-09-09 New antitumoral compounds
GB0321066.3 2003-09-09

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2009147217/04A Division RU2009147217A (ru) 2003-09-09 2009-12-18 Новые противоопухолевые соединения

Publications (2)

Publication Number Publication Date
RU2006111491A true RU2006111491A (ru) 2007-11-20
RU2395520C2 RU2395520C2 (ru) 2010-07-27

Family

ID=29226738

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2006111491/04A RU2395520C2 (ru) 2003-09-09 2004-09-09 Производные кахалалида f
RU2009147217/04A RU2009147217A (ru) 2003-09-09 2009-12-18 Новые противоопухолевые соединения

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2009147217/04A RU2009147217A (ru) 2003-09-09 2009-12-18 Новые противоопухолевые соединения

Country Status (23)

Country Link
US (1) US20070117743A1 (ru)
EP (6) EP2280027A3 (ru)
JP (4) JP4874796B2 (ru)
KR (1) KR20060073618A (ru)
CN (2) CN101531707A (ru)
AT (1) ATE393776T1 (ru)
AU (2) AU2004270471B2 (ru)
CA (1) CA2537128A1 (ru)
CY (1) CY1108226T1 (ru)
DE (1) DE602004013454T2 (ru)
DK (2) DK2664623T3 (ru)
ES (2) ES2305843T3 (ru)
GB (1) GB0321066D0 (ru)
HR (1) HRP20080330T3 (ru)
HU (1) HUE025308T2 (ru)
IL (1) IL173929A (ru)
MX (1) MXPA06002741A (ru)
NZ (4) NZ580124A (ru)
PL (1) PL1664093T3 (ru)
PT (1) PT1664093E (ru)
RU (2) RU2395520C2 (ru)
SI (1) SI1664093T1 (ru)
WO (1) WO2005023846A1 (ru)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0002952D0 (en) * 2000-02-09 2000-03-29 Pharma Mar Sa Process for producing kahalalide F compounds
GB0304367D0 (en) 2003-02-26 2003-04-02 Pharma Mar Sau Methods for treating psoriasis
US7507708B2 (en) 2003-02-26 2009-03-24 Pharma Mar, S.A.U. Antitumoral compounds
WO2009052379A2 (en) * 2007-10-19 2009-04-23 Pharma Mar, S.A. Improved antitumoral treatments
EP2252315A1 (en) * 2008-01-30 2010-11-24 Pharma Mar, S.A. Improved antitumoral treatments
EP2262522A1 (en) * 2008-03-07 2010-12-22 Pharma Mar, S.A. Improved antitumoral treatments
CN101519437B (zh) * 2009-04-09 2012-05-02 中国人民解放军第二军医大学 西沙海绵中一种环七肽类化合物及其用途
CN104725266B (zh) * 2014-04-10 2016-08-10 申俊 酰亚胺类化合物的合成方法
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (es) * 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
US4943533A (en) * 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
JPS6178719A (ja) * 1984-09-25 1986-04-22 Tanabe Seiyaku Co Ltd 総合輸液剤
DK0531472T3 (da) * 1991-03-06 2003-12-01 Merck Patent Gmbh Humaniserede monoklonale antistoffer
GB9300059D0 (en) * 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
GB9302046D0 (en) 1993-02-03 1993-03-24 Pharma Mar Sa Antiumoral compound-v
US6274551B1 (en) * 1994-02-03 2001-08-14 Pharmamar, S.A. Cytotoxic and antiviral compound
US5705511A (en) * 1994-10-14 1998-01-06 Cephalon, Inc. Fused pyrrolocarbazoles
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) * 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
EP0912559B1 (en) * 1996-07-13 2002-11-06 Glaxo Group Limited Fused heterocyclic compounds as protein tyrosine kinase inhibitors
US6235883B1 (en) * 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
GB9800569D0 (en) * 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
US6200598B1 (en) * 1998-06-18 2001-03-13 Duke University Temperature-sensitive liposomal formulation
WO2000031048A1 (en) * 1998-11-19 2000-06-02 Warner-Lambert Company N-[4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide, an irreversible inhibitor of tyrosine kinases
US7311924B2 (en) * 1999-04-01 2007-12-25 Hana Biosciences, Inc. Compositions and methods for treating cancer
UA74803C2 (ru) * 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стойкий полиморф гидрохлорида n-(3-этинилфенил)-6,7-бис(2-метоксиэтокси)-4-хиназолинамина, способ его получения (варианты) и фармацевтическое применение
GB0002952D0 (en) * 2000-02-09 2000-03-29 Pharma Mar Sa Process for producing kahalalide F compounds
MXPA03003704A (es) 2000-10-31 2004-05-04 Pharma Mar Sa Formulacion de kahalalide f.
AU2002334203C1 (en) 2001-10-19 2008-10-09 Pharma Mar, S.A. Kahalalide compounds for use in cancer therapy
CN100591691C (zh) 2002-10-18 2010-02-24 马尔药品公司 新型抗肿瘤化合物
GB0304367D0 (en) * 2003-02-26 2003-04-02 Pharma Mar Sau Methods for treating psoriasis
SI1572726T1 (sl) * 2002-10-18 2011-04-29 Pharma Mar Sau 4-metilheksanoiäśna kahalalid f spojina
US7507708B2 (en) * 2003-02-26 2009-03-24 Pharma Mar, S.A.U. Antitumoral compounds

Also Published As

Publication number Publication date
EP1918296A2 (en) 2008-05-07
AU2011202286A1 (en) 2011-06-09
PT1664093E (pt) 2008-08-07
EP1664093B8 (en) 2008-08-13
HUE025308T2 (en) 2016-01-28
RU2395520C2 (ru) 2010-07-27
JP4874796B2 (ja) 2012-02-15
US20070117743A1 (en) 2007-05-24
JP5372096B2 (ja) 2013-12-18
DK1664093T3 (da) 2008-08-18
PL1664093T3 (pl) 2008-10-31
SI1664093T1 (sl) 2008-12-31
CN1849333A (zh) 2006-10-18
CN101531707A (zh) 2009-09-16
JP2012031188A (ja) 2012-02-16
MXPA06002741A (es) 2006-06-05
EP1918296B1 (en) 2012-11-14
EP1664093A1 (en) 2006-06-07
EP2280026A2 (en) 2011-02-02
CY1108226T1 (el) 2014-02-12
DE602004013454D1 (de) 2008-06-12
WO2005023846A1 (en) 2005-03-17
HRP20080330T3 (en) 2009-04-30
DK2664623T3 (en) 2015-05-11
NZ580124A (en) 2011-01-28
EP2664623B1 (en) 2015-03-04
DE602004013454T2 (de) 2009-06-18
CA2537128A1 (en) 2005-03-17
GB0321066D0 (en) 2003-10-08
EP2280025A2 (en) 2011-02-02
EP2280026A3 (en) 2011-05-25
EP1664093B1 (en) 2008-04-30
JP2012031187A (ja) 2012-02-16
IL173929A0 (en) 2006-07-05
KR20060073618A (ko) 2006-06-28
ATE393776T1 (de) 2008-05-15
EP2280025A3 (en) 2011-05-25
EP2280027A2 (en) 2011-02-02
JP2007526904A (ja) 2007-09-20
JP2012051899A (ja) 2012-03-15
IL173929A (en) 2014-01-30
ES2536285T3 (es) 2015-05-22
AU2004270471B2 (en) 2011-06-02
CN100467482C (zh) 2009-03-11
RU2009147217A (ru) 2011-06-27
AU2011202286B2 (en) 2013-08-01
NZ545700A (en) 2010-03-26
EP1918296A3 (en) 2009-06-24
NZ589890A (en) 2011-11-25
NZ595490A (en) 2013-04-26
ES2305843T3 (es) 2008-11-01
AU2004270471A1 (en) 2005-03-17
EP2664623A1 (en) 2013-11-20
EP2280027A3 (en) 2011-05-04

Similar Documents

Publication Publication Date Title
Hruby et al. Conformation–activity relationships of opioid peptides with selective activities at opioid receptors
FI94353C (fi) Menetelmä terapeuttisesti käyttökelpoisen bradykiniiniantagonistin valmistamiseksi
Gao et al. Chemistry and biology of kahalalides
UA48974C2 (ru) Translated By PlajПЕПТИД И СПОСОБ ЕГО ПОЛУЧЕНИЯ
KR850001230A (ko) 옥타펩티드 바조프레신 길항물질의 제조방법
RU2008104802A (ru) Лиганды рецепторов меланокортинов
RU2006111491A (ru) Новые противоопухолевые соединения
PT779076E (pt) Peptidos, um metodo para a sua obtencao e um composto farmaceutico om base nestes
CA2214410A1 (en) Peptide and a method of obtaining it
CA2115246A1 (en) Lanthionine bridged peptides
RU94024278A (ru) Пептид и способ его получения
CA2026376C (en) Anticoagulant peptides
Spatola et al. Amide bond surrogates: pseudopeptides and macrocycles
EP0341603A3 (en) Atrial peptide derivatives
KR910009730A (ko) 펩티드
US5192747A (en) Anticoagulant peptides
US4371463A (en) Enzyme-resistant opiate pentapeptides
FI109541B (fi) Menetelmä bradykiniiniantagonistien valmistamiseksi
EP0151016A3 (en) Arginine vasopressin antagonists
EP0189326A3 (en) Derivatives of arginine vasopressin antagonists
AU2014332346A1 (en) Novel peptide compositions
Witkowska et al. Synthesis and biological activity profile of new analogues of the cyclic opioid peptide H‐Tyr‐c [d‐Cys‐Gly‐Phe (pNO2)‐d‐Cys]‐NH2 containing (S)‐α‐hydroxymethylcysteine in place of cysteine
Bladon Peptide Hormones and Other Biologically Active Peptides
Tamamura et al. Stereo-controlled Synthesis of [l-Arg, l/d-3-(2-Naphthyl) alanine]-type (E)-Alkene Dipeptide Isosteres and its Application to the Preparation and Biological Evaluation of Peptidomimetic Analogs of the CXCR4 Antagonist FC131
Davies Analogue and Conformational Studies on Peptide Hormones and Other Biologically Active Peptides

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20170910